DRKS00000756已完成2 期
A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson's disease administered once daily for 28 Weeks - CONFIDENT-PD
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 425
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 35 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Key inclusion criteria:
- •1) Confirmed diagnosis of early stage idiopathic PD within the 2 years prior to screening
- •2) Subjects who have not taken and / or are not currently receiving any PD treatment
- •Other inclusion criteria apply
排除标准
- •Key exclusion criteria:
- •1) female of child-bearing potential
- •2) history of neurosurgical procedures for PD
- •3) history of severe psychiatric illness
- •Other exclusion criteria apply
研究者
相似试验
进行中（未招募）
不适用
Investigation of Cogane (PYM50028) in early stage Parkinson's diseaseEUCTR2010-018534-44-HUPhytopharm plc408
进行中（未招募）
不适用
Investigation of Cogane (PYM50028) in early stage Parkinson's diseaseEUCTR2010-018534-44-CZPhytopharm plc408
进行中（未招募）
不适用
Investigation of Cogane (PYM50028) in early stage Parkinson's diseaseEarly-Stage Parkinson’s DiseaseMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-018534-44-DEPhytopharm plc408
进行中（未招募）
1 期
Investigation of Cogane (PYM50028) in early stage Parkinson's diseaseEarly-Stage Parkinson’s DiseaseMedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disordersEUCTR2010-018534-44-GBPhytopharm plc408
已完成
不适用
A phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to compare the efficacy, safety and tolerability of PSD502, delivered topically onto the upper vagina and cervix, to placebo in controlling discomfort/pain intensity in subjects undergoing outpatient hysteroscopyISRCTN46090514Plethora Solutions Limited (UK)24